ALXO vs JNJ · $207.2M cap vs P/E 17, rev $49.37B
Alx Oncology Holdings (ALXO) versus Johnson & Johnson (JNJ) — a side-by-side from cached financials, not a winner call.
Alx Oncology Holdings (ALXO) is a biotechnology company listed on US.
Johnson & Johnson (JNJ) is a drug manufacturers - general company listed on US. It is led by Joaquin Duato.
ALXO does not have a complete income-statement cache yet.
Latest reported JNJ revenue for 2026-06-28 was $49.37B. Net income was $10.77B. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
ALXO currently screens at market cap $207.2M. JNJ currently screens at market cap $375.37B and trailing P/E 17.4.
Not investment advice. Open the ALXO and JNJ stock pages for the full models.
Not investment advice.